Ketamine Infusion Therapy Insurance Denied: Appeal

IV ketamine infusions are emerging as a breakthrough treatment for severe, treatment-resistant depression, PTSD, and certain chronic pain conditions. Despite their clinical effectiveness, ketamine infusions are denied by virtually every commercial insurer. Here is why denials happen, and what you can do about it.

What Is Ketamine Infusion Therapy?

Ketamine is an FDA-approved anesthetic that, at sub-anesthetic doses administered intravenously, produces rapid antidepressant effects—often within hours to days. This is a stark contrast to traditional antidepressants, which take weeks to months to work. For patients with treatment-resistant depression (TRD), suicidal ideation, or severe PTSD, this speed can be life-saving.

IV ketamine infusions are typically given as a series of 6 infusions over 2–3 weeks, followed by maintenance infusions every 4–8 weeks depending on response.

Spravato vs. IV Ketamine: The Coverage Distinction

In 2019, the FDA approved Spravato (esketamine) nasal spray—a closely related molecule—specifically for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Unlike IV ketamine, Spravato has specific FDA approval, an ICD-10 billing pathway, and established coverage policies with most commercial insurers and Medicare (with Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization).

IV ketamine, by contrast, is an FDA-approved drug used off-label for depression and pain. Most insurers distinguish between the two, covering Spravato under rigorous criteria while denying IV ketamine as "investigational" for psychiatric indications. This distinction matters enormously for your appeal strategy.

Why Insurers Deny Ketamine Infusion Therapy

Not FDA-Approved for Depression/Pain (Off-Label)

IV ketamine's antidepressant use is off-label. Insurers routinely deny off-label treatments when an FDA-approved alternative exists—and argue that Spravato satisfies the need for an FDA-approved NMDA-receptor antagonist.

Step Therapy Requirements Not Documented

Even where coverage is theoretically possible, insurers require documentation that multiple prior treatments have failed. For TRD, this typically means 2–4 antidepressant trials at therapeutic doses for adequate duration, plus augmentation strategies (adding lithium, atypical antipsychotics, thyroid hormone). Without explicit documentation of failed trials, the denial stands.

Classified as Experimental/Investigational

Many insurer coverage policies explicitly classify IV ketamine infusions as experimental for all psychiatric indications. These policies have not kept pace with clinical evidence—multiple randomized controlled trials and APA guidance now support ketamine for TRD.

Chronic Pain Denials

For pain indications (CRPS, refractory migraine, fibromyalgia), IV ketamine is even less consistently covered. Denials cite lack of FDA approval, limited long-term efficacy data, and availability of opioid or non-opioid alternatives.

How to Appeal a Ketamine Infusion Denial

Document Treatment-Resistant Depression Rigorously

The single most important factor in a ketamine denial appeal is a comprehensive treatment history. Compile documentation for every antidepressant or mood stabilizer tried: drug name, dose, duration, reason for discontinuation (inadequate response vs. side effects). Use the Massachusetts General Hospital Treatment-Resistant Depression staging system or the ATHF (Antidepressant Treatment History Form) to structure this documentation.

For TRD, document specifically: at least 2 adequate trials of antidepressants from different classes, at least one augmentation strategy, and ideally documented consideration or trial of ECT or TMS (see our ECT and TMS guides separately).

Cite American Psychiatric Association Guidance

The APA has issued multiple statements supporting ketamine for TRD when standard treatments have failed. Quote from APA Council on Research reports: "Ketamine's rapid antidepressant effects represent a genuine advance for patients with treatment-resistant depression, particularly those at high risk for suicide." This is not an experimental treatment by APA standards.

Lead With Suicidality If Present

If you have a history of suicidal ideation, document it prominently. The FDA specifically approved Spravato for MDD with acute suicidal ideation—an insurer who covers Spravato for suicidality but denies IV ketamine on suicidality grounds may be acting inconsistently. Your physician's documentation that rapid-onset antidepressant treatment is clinically necessary for suicide prevention is a powerful appeal argument.

Argue Cost-Effectiveness

Paradoxically, a series of ketamine infusions may cost less than extended hospitalization for a patient with severe, refractory depression. Include this economic argument in your appeal: "Covering this outpatient treatment prevents hospitalizations that are far more costly."

Consider Spravato as a Bridge

If IV ketamine is denied and you qualify for Spravato, ask your psychiatrist about transitioning—Spravato (esketamine) nasal spray administered in a certified healthcare setting has insurance coverage pathways and similar (though not identical) efficacy to IV ketamine.

Request External Independent Review: Complete Guide" class="auto-link">External Review

External reviewers applying standard clinical criteria are more likely to find that IV ketamine is appropriate for documented TRD than an insurer's internal policy team using a blanket "experimental" classification. File for IRO review promptly.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?